Royalty Pharma raises 2026 receipts guidance; Q3 net income falls on $150 million charge
Royalty Pharma reported third quarter 2026 Portfolio Receipts of $890 million, up 9% from a year earlier, and raised its full-year 2026 Portfolio Receipts guidance to $3,500 million to $3,550 million. Net income attributable to Royalty Pharma plc fell to $145 million from $284 million, mainly because of a $150 million non-cash impairment on pelacarsen after a Phase 3 trial missed its primary endpoint.
Key points
- Portfolio Receipts rose 9% to $890 million; Royalty Receipts rose 9% to $883 million.
- 2026 Portfolio Receipts guidance raised to $3,500 million to $3,550 million from $3,400 million to $3,500 million.
- Net income attributable to Royalty Pharma plc was $145 million, versus $284 million a year earlier, after a $150 million impairment tied to pelacarsen.
- Net cash provided by operating activities was $686 million, down 2% from $703 million.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.